Stay updated on Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial
Sign up to get notified when there's something new on the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page.

Latest updates to the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page
- Check3 days agoChange DetectedThe page now includes Data sharing and IPD Plan sections detailing data-access policies and related documents, and the previous revision tag 'Revision: v3.6.4' was removed.SummaryDifference100%

- Check10 days agoChange DetectedDeleted entries in the Study Documents section that provided access to major trial documents (Statistical Analysis Plan, Study Protocol) and the data-sharing/IPD information, reducing availability of key methodological and transparency resources for the DREAMM-3 trial.SummaryDifference16%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4. This indicates a minor update/patch to the page’s metadata.SummaryDifference0.0%

- Check38 days agoChange DetectedThe page now lists 136 investigational sites across various countries and updates trial durations/outcome timeframes (e.g., weeks-based horizons), reflecting the current scope of the DREAMM-3 study.SummaryDifference4%

- Check46 days agoChange DetectedThe page's related topics were expanded to include Multiple myeloma and MedlinePlus Genetics, and the site revision was updated from v3.6.0 to v3.6.3.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page now indicates the study is no longer recruiting participants, clarifying current enrollment status. Additionally, new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) were added and the Intervention/Treatment label was reformatted.SummaryDifference0.3%

Stay in the know with updates to Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page.